Oxaliplatin extravasation has been associated with local pain and inflammation which may be severe and lead to complications including necrosis. Recent case reports suggest that oxaliplatin may be better classified as an irritant when extrava-sated. The optimal management of oxaliplatin extravasation however remains uncertain. Cold compress may cause local vasoconstriction and reduce cellular injury. However, it may potentially precipitate or worsen peripheral neuropathy. Warm compress may increase drug removal by local vasodilation and avoid peripheral neuropathy. However, it may potentially increase cellular uptake and hence injury. Further research into this area is needed.
Sanofi-Synthelabo. Eloxatin: summary of product characteristics. New York, 9 August, 2002.
3.
BC Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: prevention and management of extravasation of chemotherapy. BC Cancer Agency, 1 December, 2004.
4.
Schrijvers DL.Extravasation: a dreaded complication of chemotherapy. Ann Oncol2003; 14Suppl 3: iii26-iii30.
5.
Fenchel K, Karthaus M.Cytotoxic drug extravasation. Antibiot Chemother2000; 50: 144-148.
6.
The National Extravasation Information Service. 6 January 2004: Protocol for management of chemotherapy extra-vasation. Retrieved 7 January 2005, from http://www.extravasation.org.uk/home.html
7.
Doyle S. Personal communication. Medical Marketing Manager, Oncology and Haematology, Sanofi-Synthelabo Australia Pty Ltd. 21 July, 2004.
8.
Baur M, Kienzer HR, Rath T, et al. Extravasation of oxaliplatin (Eloxatin 2000; 23(5): 468-71. ®) - clinical course. Onkologie
9.
Kennedy JG, Donahue JP, Hoang B, et al.Vesicant characteristics of oxaliplatin following antecubital extra-vasation. Clin Oncol (R Coll Radiol)2003; 15(5): 237-239.
10.
Foo KF, Michael M, Toner G, et al.A case report of oxaliplatin extravasation. Ann Oncol2003; 14(6): 961-962.
11.
Eckert R, Maier KP.Necrotizing panniculitis after extra-vasation of oxaliplatin. Ann Oncol2002; 13(Suppl 5): 29-29 (abstract 103).
12.
Kretzschmar A, Thuss-Patience P, Pink D, et al.Extra-vasations of oxaliplatin. Proc Am Soc Clin Oncol2002; 21: A2900-A2900.
13.
Kretzschmar A, Pink D, Thuss-Patience P, et al.Extra-vasations of oxaliplatin. J Clin Oncol2003; 21(21): 4068-4069.
14.
Ignoffo R, Friedman M.Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drug. Cancer Treat Rev1980; 7: 17-27.
15.
Cox K, Stuart-Harris R, Abdini G, et al.The management of cytotoxic-drug extravasation: guidelines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust1988; 148: 185-189.
16.
Bertelli G, Gozza A, Forno GB, et al.Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol1995; 13(11): 2851-2855.
17.
Solimando DA Jr, Bressler LR, Kintzel PE, et al.Drug information handbook for oncology, second edition. Lexi-Comp, 1999: 596-604.
18.
Sanofi-Synthelabo. Eloxatin: summary of product characteristics (Europe). France, 1 October, 1999.
19.
Dorr RT, Alberts DS, Stone A.Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. Cancer Treat Rep1985; 69(4): 431-437.
20.
Larson DL.Treatment of tissue extravasation by antitumor agents. Cancer1982; 49(9): 1796-1799.
21.
Larson DL.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg1985; 75(3): 397-405.
